Trial reportClinical research in cardiology : official journal of the German Cardiac Society2011
Reducing elevated heart rate in patients with multiple organ dysfunction syndrome by the I (f) (funny channel current) inhibitor ivabradine : MODI (f)Y trial.
Trial report in Clinical research in cardiology : official journal of the German Cardiac Society, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 45 citations in OpenAlex.
- [Relationship between cardiac output, heart rate and microcirculation in patients with multiorgan dysfunction syndrome].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2024Trial
- [Prognostic relevance of tissue oxygen saturation in patients in the early stage of multiple organ dysfunction syndrome].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2019Trial
- A prospective, randomized trial of continuous lateral rotation ("kinetic therapy") in patients with cardiogenic shock.Clinical research in cardiology : official journal of the German Cardiac Society · 2012Trial
- Lasting reduction of heart transplant tachycardia with ivabradine is effective and well tolerated: results of 48-month study.Clinical research in cardiology : official journal of the German Cardiac Society · 2012Trial
- Article
- The Prognostic Value of a Liver Function Test Using Indocyanine Green (ICG) Clearance in Patients with Multiple Organ Dysfunction Syndrome (MODS).Journal of clinical medicine · 2024Article
- Predicting the Need for Renal Replacement Therapy Using a Vascular Occlusion Test and Tissue Oxygen Saturation in Patients in the Early Phase of Multiorgan Dysfunction Syndrome.Journal of clinical medicine · 2022Article
- Ivabradine: Evidence and current role in cardiovascular diseases and other emerging indications.Indian heart journal · 2018Review
- Continuous blood purification ameliorates clinical signs and corrects the plasma phospholipid levels of patients with multiple organ dysfunction syndromes.Journal of clinical laboratory analysis · 2018Article
- Ivabradine in Management of Heart Failure: a Critical Appraisal.Current heart failure reports · 2016Article
- Advances in the management of heart failure: the role of ivabradine.Vascular health and risk management · 2016Review
- Ivabradine: a preliminary observation for a new terapeutic role in patients with multiple organ dysfunction syndrome.Clinical research in cardiology : official journal of the German Cardiac Society · 2014Article
- I(f) blocking potency of ivabradine is preserved under elevated endotoxin levels in human atrial myocytes.Journal of molecular and cellular cardiology · 2014Article
- Heart rate before ICU discharge: a simple and readily available predictor of short- and long-term mortality from critical illness.Clinical research in cardiology : official journal of the German Cardiac Society · 2013Article
- Ivabradine in pulmonary arterial hypertension: can we delay the need for parenteral prostanoid therapy?Clinical research in cardiology : official journal of the German Cardiac Society · 2013Article
- Ivabradine: potential clinical applications in critically ill patients.Clinical research in cardiology : official journal of the German Cardiac Society · 2013Review
- Intracardiac origin of heart rate variability, pacemaker funny current and their possible association with critical illness.Current cardiology reviews · 2013Review
- Ivabradine: an intelligent drug for the treatment of ischemic heart disease.Molecules (Basel, Switzerland) · 2012Review
- Safe and well-tolerated treatment with ivabradine in systemic sclerosis affected by pulmonary hypertension.Clinical research in cardiology : official journal of the German Cardiac Society · 2012Article
- Heart rate as an independent risk factor in patients with multiple organ dysfunction: a prospective, observational study.Clinical research in cardiology : official journal of the German Cardiac Society · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart rate (HR) is of relevant prognostic value not only in the general population and patients with cardiovascular disease, but also in critically ill patients with multiple organ dysfunction syndrome (MODS). An elevated HR in MODS patients is associated with a worse prognosis. Beta-blocker (BB) administration has been shown to reduce mortality in MODS. In most cases, negative inotropic effects prevent administration of BBs in MODS patients. In this trial we investigate, whether the "funny current" (I (f)) channel inhibitor ivabradine is able and apt to reduce pathologically elevated HR in MODS patients. We hypothesize that critically ill patients could derive particular benefit from the specific HR-lowering agent ivabradine.
methodsMODI (f)Y is a prospective, single centre, open label, randomized, controlled two arms, phase II-trial to evaluate the potential of ivabradine to reduce an elevated HR in MODS patients. The primary end point is the proportion of patients with a reduction of HR by at least 10 beats per minute (bpm) within 4 days. This trial will randomize 70 patients (men and women, aged ≥18 years) with newly diagnosed MODS, with an elevated HR (sinus rhythm with HR ≥90 bpm) and contraindications to BB therapy. Treatment period will last for 4 days. All patients will be followed for 6 months.
resultsThe first patient was randomized on May 21, 2010.
conclusionsThe MODI (f)Y trial is the first application of ivabradine as a pure heart rate reducing agent in MODS patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.